antifungals
-
Scynexis antifungal drug secures FDA nod; first approval in new class in 20 years
The FDA has approved Brexafemme, a Scynexis antifungal drug, for treating vaginal yeast infections. The drug is the biotech’s first FDA-approved product and it also represents the first new antifungal drug class in 20 years.
-
New antibiotics are urgently needed, but economics stand in the way
In the wake of Achaogen’s bankruptcy, experts discussed ways to ensure new treatments are available to combat drug-resistant bacteria that threaten a post-antibiotic world.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.